Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up

Dasatinib is the most potent BCR-ABL inhibitor, with 325-fold higher potency than imatinib against unmutated BCR-ABL in vitro. Studies have demonstrated the benefits of dasatinib 70 mg twice daily in patients with accelerated-phase chronic myeloid leukemia intolerant or resistant to imatinib. A phas...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood
Hauptverfasser: Kantarjian, Hagop, Cortes, Jorge, Kim, Dong-Wook, Dorlhiac-Llacer, Pedro, Pasquini, Ricardo, DiPersio, John, Müller, Martin C., Radich, Jerald P., Khoury, H. Jean, Khoroshko, Nina, Bradley-Garelik, M. Brigid, Zhu, Chao, Tallman, Martin S.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Hematology 2009
Schlagworte:
Clinical Trials and Observations
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4916944/
https://ncbi.nlm.nih.gov/pubmed/19369231
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-11-186817
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge